OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract surgery. The primary objective is to evaluate the efficacy and safety of OCS-01 compared to placebo and the secondary objective is to evaluate the optimal dosing frequency (once a day \[QD\] or twice a day \[BID\]).
Epistemonikos ID: 2f4f5a006d463256703c43697f3de23e4c024dca
First added on: May 22, 2024